Company Description

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer.

The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001.

It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

YS Biopharma Co., Ltd.

Country	China
Founded	2002
Industry	Biotechnology
Sector	Healthcare
Employees	754
CEO	Dr. Hui Shao Ph.D.

Contact Details

Address: Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park Daxing District, Beijing, F4 102629 China
Phone	17327133678
Website	yishengbio.com

Stock Details

Ticker Symbol	YS
Exchange	NASDAQ
Fiscal Year	April - March
Reporting Currency	USD
CIK Code	0001946399
ISIN Number	KYG9845F1090
SIC Code	2834

Key Executives

Name	Position
Gang Li	Head of Marketing and Sales
Dr. Yuan Liu Ph.D.	Head of Vaccine Research
Dr. Hui Shao Ph.D.	President, Chief Executive Officer and Executive Director
Chunyuan Wu CPA	Chief Financial Officer and Director
Dr. Zenaida Reynoso Mojares	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Apr 19, 2024	6-K	Report of foreign issuer
Apr 18, 2024	6-K	Report of foreign issuer
Apr 9, 2024	6-K	Report of foreign issuer
Apr 3, 2024	6-K	Report of foreign issuer
Mar 5, 2024	6-K	Report of foreign issuer
Feb 23, 2024	6-K	Report of foreign issuer
Feb 22, 2024	6-K	Report of foreign issuer
Feb 20, 2024	6-K	Report of foreign issuer
Feb 20, 2024	6-K	Report of foreign issuer
Feb 16, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals

View All SEC Filings